Clinical trial for Renal Cell Carcinoma
Official title Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)
ClinicalTrials.gov ID: NCT06770855
What this study is testing
- What it's testing
- The study wants to see if patients who have surgery to remove all visible cancer and then stop immune drugs can stay cancer‑free for 12 months.
- Who it's for
- It looks for adults with metastatic clear cell kidney cancer who have not progressed after at least 6 months of immune therapy.
- What's involved
- Participants will have surgery to remove all tumors, then stop their immune drugs. They will have follow‑up visits and scans to check for cancer.
- Time commitment
- The study lasts about a year, with regular clinic visits and imaging to monitor the patient’s status.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically or cytologically confirmed diagnosis of clear cell renal cell carcinoma (mixed histology acceptable but must have clear cell component)
- Metastatic clear cell RCC with 5 or fewer metastases at enrollment (excluding pulmonary nodules \<1.0cm)
- Stable disease or partial response as assessed by investigators following at least 6 months of immune checkpoint blockade-based therapy.
- Has disease amenable for total consolidative focal therapy (this will be determined by a multidisciplinary team which may include a combination of...
- ECOG performance status \< 2
You likely can't join if
- people who have progressed during the first 6 months of immune checkpoint-blockade based therapy as determined by study investigator.
- people who have a need for urgent focally directed therapy (i.e. symptomatic brain or spinal metastases).
- Any female of child-bearing potential who has a positive urine pregnancy test within 72 hours before screening.
See the full eligibility criteria
- Histologically or cytologically confirmed diagnosis of clear cell renal cell carcinoma (mixed histology acceptable but must have clear cell component)
- Metastatic clear cell RCC with 5 or fewer metastases at enrollment (excluding pulmonary nodules \<1.0cm)
- Stable disease or partial response as assessed by investigators following at least 6 months of immune checkpoint blockade-based therapy.
- Has disease amenable for total consolidative focal therapy (this will be determined by a multidisciplinary team which may include a combination of medical oncologists, urologists, treatment radiologists, and radiation...
- ECOG performance status \< 2
- Must have archival tissue (slide or Formalin-Fixed Paraffin-Embedded tissue) preceding prior systemic treatment for comparison to tissue from consolidation
- Consolidation surgery and biopsies are strongly encouraged to be within 42 days +/- 7 days of holding systemic therapy.
- people who have progressed during the first 6 months of immune checkpoint-blockade based therapy as determined by study investigator.
- people who have a need for urgent focally directed therapy (i.e. symptomatic brain or spinal metastases).
- Any female of child-bearing potential who has a positive urine pregnancy test within 72 hours before screening. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
The study team makes the final eligibility decision.
Where it is enrolling
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.